Pharmacovigilance inspections in the EU can be routine, for-cause, pre-authorisation or re-inspections, and they can be announced or unannounced. The revised GVP Module III (Rev 2), in effect since 10 September 2026, is explicit that marketing authorisation holders should always be "inspection-ready" [1]. In practice, readiness is not a project that starts when the notification letter arrives. It is the state of your pharmacovigilance system master file (PSMF), procedures, training and records on an ordinary day.

This checklist reflects GVP Module III Rev 2 and Implementing Regulation (EU) No 520/2012 as amended by Implementing Regulation (EU) 2025/1466, which applies from 12 February 2026 [1][2][3].

What changed in 2026

Three changes are worth checking first, because older templates and procedures will not reflect them.

  • Deviations in the PSMF. Any major or critical deviations from pharmacovigilance procedures, their impact and their management must now be documented in the PSMF until resolved (IR Art 4(3)) [2].
  • Subcontract content. Pharmacovigilance subcontracts must describe the third party's roles and responsibilities, safety data exchange where relevant, audit and inspection arrangements, and the third party's agreement to be audited by or on behalf of the MAH and inspected by competent authorities. Third parties may not further subcontract without the MAH's written consent (IR Art 6(3)–(4)) [2].
  • Vendor audit and inspection. Subcontracted third parties must be audited by or on behalf of the MAH on a risk basis and may be inspected by competent authorities, even if the inspection clause is not yet in the contract (IR Art 13(1a)) [2]. Module III Rev 2 reflects this in its scope of sites to be inspected [1].

How inspections are planned

Module III Rev 2 describes a risk-based approach. For centrally authorised products, an MAH should in principle be inspected within four years of the authorisation of its first medicinal product and then on a four-year cycle, shortened or lengthened according to ongoing risk assessment [1]. Factors that may raise priority include:

AreaExamples of risk factors listed in Module III Rev 2
Inspection historyPrevious compliance findings (including GCP, GMP, GLP, GDP); recommended re-inspection date
ProductAdditional pharmacovigilance or risk minimisation activities; safety-related conditions; additional monitoring; high EU exposure; few alternatives
MAHNever inspected; first EU authorisation; many products; limited resources; mergers or acquisitions; concerns raised outside the EU
PV systemExtent of subcontracting; change of QPPV; safety database changes or migrations; changes to contracts or sites; transfer of PSMF management

If several of these apply to you, assume an inspection is likely sooner rather than later.

Checklist 1: the PSMF

The PSMF is usually the first document inspectors request and the lens through which they read everything else.

  • Location and availability. The PSMF is located at the EU site where the main pharmacovigilance activities are performed or where the QPPV operates, and is permanently and immediately available for inspection at that site (IR Art 7) [2]. A copy must be provided within 7 days of a request from a national competent authority or the Agency [4].
  • Content per IR Art 2. QPPV details, responsibilities, CV and back-up arrangements; organisational structure and the sites where key activities are performed; computerised systems and databases; process descriptions; quality system, including training and record management; and subcontracting [2].
  • Annex per IR Art 3. Product list, list of procedures, list of subcontracts, QPPV-delegated tasks, scheduled and completed audits, performance indicators, other PSMFs held, and the logbook [2].
  • Version control and logbook. The PSMF and annex are version-controlled and dated (Art 4(2)); alterations over the last five years are recorded with date, responsible person and reason (Art 5(4)) [2].
  • Audit notes and deviations. Main audit findings are noted in the PSMF until corrective actions are fully implemented (Directive 2001/83/EC Art 104(2)) [5]; major or critical deviations are documented until resolved (IR Art 4(3)) [2].
  • Accuracy test. Pick five statements in the PSMF and ask whether a staff member could demonstrate each one with live records. If not, either the PSMF or the process needs correcting.

Checklist 2: procedures and quality system

  • Coverage. Procedures exist for each process inspectors routinely examine: ICSR collection, assessment, follow-up and reporting; PSURs; signal management; RMP and risk minimisation implementation; safety communications; product information updates; non-interventional studies; and the quality system itself [1].
  • Compliance management. Processes ensure data quality, integrity and completeness, including avoiding duplicate submissions (IR Art 11(1)(d)) [2].
  • Signal management update. Procedures describe how EudraVigilance data are monitored and used alongside other sources, reflecting the end of the MAH pilot and the deletion of standalone signal notifications [6].
  • Business continuity. Instructions for urgent situations and business continuity are in place (IR Art 10(4)) [2].
  • Audits. Risk-based audits at regular intervals by people with no direct involvement in the audited activity, with reports, CAPA and follow-up documented (IR Art 13) [2].

Checklist 3: people and training records

  • QPPV. Appropriately qualified, permanently and continuously available, residing and operating in the EU or EEA, with documented back-up; if the QPPV is not medically trained, documented assistance from a medically trained person (Directive Art 104(3); IR Art 10(1)) [5][2][7].
  • Roles. Job descriptions for managerial and supervisory staff and an organisational chart; the QPPV has sufficient authority to influence the quality system (IR Art 10(2)) [2].
  • Training. Initial and continued training for everyone involved in pharmacovigilance activities, with training plans and records available for audit or inspection (IR Art 10(3)) [2]. Include staff outside the safety team who may receive adverse event information, such as medical information, commercial and patient support.
  • Vendors. Evidence that subcontracted staff are trained on the relevant MAH procedures or equivalent, as defined in the contract.

Checklist 4: records and data

  • Traceability. Records show how safety concerns were investigated, the timelines and the decisions, including date and decision-making process (IR Art 12(1)) [2].
  • Retention. PSMF elements are kept at least five years after the system is formally terminated; product pharmacovigilance data and documents for as long as the product is authorised and at least ten years after the authorisation ceases (IR Art 12(2)) [2].
  • Reconciliation. Regular reconciliation between the safety database and other sources (medical information, complaints, partners, studies), with discrepancies investigated.
  • Compliance metrics. ICSR and PSUR timeliness and other performance indicators are tracked, reviewed and acted on, not merely reported.

Inspection day

Module III Rev 2 lists the MAH's responsibilities during an inspection [1]. Translated into practical preparation:

  1. Confirm consent from sites. Every site selected, including subcontracted third parties and their subcontractors, agrees to be inspected before the inspection takes place.
  2. Provide documents on time. Make requested information available within the deadline set, both before and during the inspection. Prepare a document request tracker and a single person responsible for it.
  3. Make the right people available. Staff who perform pharmacovigilance activities, not only managers, should be present and able to explain what they do and show records.
  4. Single point of access. Ensure relevant pharmacovigilance data are accessible at a single point within the EU.
  5. Plan for remote formats. The inspectorate may decide case by case to inspect remotely, for example where key sites are outside the EU; test screen sharing and secure remote access to the PSMF and systems in advance [1].
  6. Respond with a proportionate CAPA plan. Address findings with timely corrective and preventive actions, prioritising critical and major findings [1]. Root cause analysis matters more than speed alone.

A realistic mock inspection

A mock inspection is most useful when it follows the scope an inspector would use: pick a product, trace several ICSRs from receipt to submission, follow a signal from detection to conclusion, and check that an RMP commitment and a product information change were implemented as agreed. Then compare what you found with what the PSMF says.

If you would like an independent view of your pharmacovigilance system before inspectors form theirs, contact us.

Sources

  1. GVP Module III Rev 2: Pharmacovigilance inspections, effective 10 September 2026 (EMA)
  2. Implementing Regulation (EU) No 520/2012, consolidated version 12.02.2026 (EUR-Lex)
  3. Implementing Regulation (EU) 2025/1466 amending Implementing Regulation (EU) No 520/2012 (EUR-Lex)
  4. GVP Module II Rev 2: Pharmacovigilance system master file (EMA)
  5. Directive 2001/83/EC, consolidated version 01.01.2025, Article 104 (EUR-Lex)
  6. EMA Q&A on Implementing Regulation (EU) 2025/1466, EMA/243145/2025 Rev 2 (EMA)
  7. GVP Module I: Pharmacovigilance systems and their quality systems (EMA)

This article is for information only and is not medical or regulatory advice.

Related services: PV system, PSMF and GVP inspection readiness and pharmacovigilance training.

Follow Safety Strategy on LinkedIn (opens in a new tab) for new articles and updates. Back to all news